Jeito Capital, a private equity firm, led a €35m round in NMD Pharma, a biotech company, with participation from INKEF Capital, Novo Holdings, Roche Venture Fund and Lundbeck. “The closing of this financing round is a testament to the clear vision and ambition of NMD Pharma to become a leader in the field of neuromuscular diseases. It reflects decades of scientific work in the area and the unique potential of our people for growing our development pipeline. Furthermore, we are intrigued with the broad clinical utility of our CLC-1 inhibitor portfolio and look forward to continuing our efforts to provide treatments for patients suffering from neuromuscular diseases. We are pleased to welcome Jeito Capital with Sabine Dandiguian to our Board. Her network of industry contacts and strategic business advice will be invaluable to us as we grow and expand our business," Thomas Holm Pedersen, NMD Pharma CEO.